

## Rybrevant® (amivantamab-vmjw) – New indication

- On September 19, 2024, <u>J&J announced</u> the <u>FDA approval</u> of <u>Rybrevant (amivantamab-vmjw)</u>, in combination with carboplatin and pemetrexed, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EFGR tyrosine kinase inhibitor (TKI).
- Rybrevant is also approved for:
  - In combination with lazertinib for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations
  - In combination with carboplatin and pemetrexed for first-line treatment of NSCLC with EGFR exon 20 insertion mutations
  - As a single agent for previously treated NSCLC with EGFR exon 20 insertion mutations.
- The approval of Rybrevant for the new indication was based on MARIPOSA-2, a randomized, openlabel study in patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations and progressive disease on or after receiving <u>Tagrisso®</u> (osimertinib). Patients were randomized to Rybrevant in combination with carboplatin and pemetrexed, carboplatin and pemetrexed, or Rybrevant as part of another combination regimen. The major outcome measure was progression-free survival (PFS). Overall survival (OS) and overall response rate (ORR) were key secondary outcome measures.
  - Median PFS was 6.3 months in the Rybrevant + carboplatin + pemetrexed arm vs. 4.2 months in the carboplatin + pemetrexed arm (hazard ratio 0.48, 95% CI: 0.36, 0.64; p < 0.0001).</li>
  - The ORR was 53% in the Rybrevant + carboplatin + pemetrexed arm vs. 29% in the carboplatin + pemetrexed arm (p < 0.0001).</li>
  - At the prespecified second interim analysis of OS, with 85% of the deaths needed for the final analysis, there was no statistically significant difference in OS.
- The recommended dose of Rybrevant, when used in combination with carboplatin and pemetrexed, is based on body weight.

Body weight at baseline	Recommended dose	Dosing schedule
< 80 kg	1400 mg	Weekly (total of 4 doses) from weeks 1 to 4
		<ul> <li>Week 1 - split infusion on day 1 and day 2</li> </ul>
		<ul> <li>Weeks 2 to 4 - infusion on day 1</li> </ul>
		<ul> <li>Weeks 5 and 6 - no dose</li> </ul>
	1750 mg	Every 3 weeks starting at week 7 onwards
≥ 80 kg	1750 mg	Weekly (total of 4 doses) from weeks 1 to 4
		<ul> <li>Week 1 - split infusion on day 1 and day 2</li> </ul>
		<ul> <li>Weeks 2 to 4 - infusion on day 1</li> </ul>
		Weeks 5 and 6 - no dose
	2100 mg	Every 3 weeks starting at week 7 onwards

• Refer to the Rybrevant drug label for dosing for its other indications.

## Optum

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.